Combination Effect of Regulatory T-Cell Depletion and Ionizing Radiation in Mouse Models of Lung and Colon Cancer

Purpose To investigate the potential of low-dose cyclophosphamide (LD-CTX) and anti-CD25 antibody to prevent activation of regulatory T cells (Tregs) during radiation therapy. Methods and Materials We used LD-CTX and anti-CD25 monoclonal antibody as a means to inhibit Tregs and improve the therapeut...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of radiation oncology, biology, physics Vol. 92; no. 2; pp. 390 - 398
Main Authors Son, Cheol-Hun, MS, Bae, Jae-Ho, MD, PhD, Shin, Dong-Yeok, PhD, Lee, Hong-Rae, MS, Jo, Wol-Soon, PhD, Yang, Kwangmo, MD, PhD, Park, You-Soo, PhD
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.06.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Purpose To investigate the potential of low-dose cyclophosphamide (LD-CTX) and anti-CD25 antibody to prevent activation of regulatory T cells (Tregs) during radiation therapy. Methods and Materials We used LD-CTX and anti-CD25 monoclonal antibody as a means to inhibit Tregs and improve the therapeutic effect of radiation in a mouse model of lung and colon cancer. Mice were irradiated on the tumor mass of the right leg and treated with LD-CTX and anti-CD25 antibody once per week for 3 weeks. Results Combined treatment of LD-CTX or anti-CD25 antibody with radiation significantly decreased Tregs in the spleen and tumor compared with control and irradiation only in both lung and colon cancer. Combinatorial treatments resulted in a significant increase in the effector T cells, longer survival rate, and suppressed irradiated and distal nonirradiated tumor growth. Specifically, the combinatorial treatment of LD-CTX with radiation resulted in outstanding regression of local and distant tumors in colon cancer, and almost all mice in this group survived until the end of the study. Conclusions Our results suggest that Treg depletion strategies may enhance radiation-mediated antitumor immunity and further improve outcomes after radiation therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0360-3016
1879-355X
DOI:10.1016/j.ijrobp.2015.01.011